CARLSBAD, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (Nasdaq: RDEA) today announced that its President and Chief Executive
Officer, Barry D. Quart, PharmD, will participate in the "In Search of the
Next HIV Treatment" panel discussion at the RBC Capital Markets 2007
Healthcare Conference on Wednesday, December 12, 2007 at 1:30 p.m. (ET) at
the Westin Times Square Hotel in New York City. A live audio webcast of the
presentation and panel discussion will be accessible through Ardea's
Investor Center web site at http://www.ardeabio.com.
Event: RBC Capital Markets Healthcare Conference
Presenter: Barry D. Quart, PharmD, President and Chief Executive Officer,
Date: Wednesday, December 12, 2007
Time: 1:30 p.m. Eastern Time
Location: The Westin Times Square, New York City
About Ardea Biosciences, Inc.
Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to have active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases planned for the first half of 2008.
Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which is in a Phase 1 clinical trial in advanced cancer patients; RDEA806 for gout, which is expected to enter a Phase 2 efficacy trial in the first half of 2008. Ardea also is developing a next-generation NNRTI and a next-generation MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of having active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases in the first half of 2008, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
|SOURCE Ardea Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved